Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report

Author(s): Gwen Klinkner, DNP, RN, BC-ADM, CDCES, FADCES, Maggie Steingraber-Pharr, MSN, RN, FNP-BC

Contact Hours 1.00

CERP A 1.00

Pharmacology Hours 1.00

Expires Mar 01, 2026

Topics: Endocrine

Population: Adult

Member: Free
NonMember: $10.00

Added to Collection

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

Sodium-glucose cotransporter-2 inhibitors are now considered second-line treatment agents for type 2 diabetes and offer a unique treatment approach with added cardiorenal benefits. Drugs in this class increase the risk of euglycemic diabetic ketoacidosis, which may be difficult to diagnose if clinicians are not aware of the risk factors and subtle symptoms. This article describes a case of euglycemic diabetic ketoacidosis in a patient with coronary artery disease who was taking a sodium-glucose cotransporter-2 inhibitor and experienced acute mental status changes immediately after heart catheterization.


  • Identify at least 3 precipitating factors for euglycemic DKA.
  • Discuss clinical effects of sodium-glucose cotransporter-2 inhibitors and expected assessments needed after prescribing.
  • Describe 2-3 strategies to mitigate risk of euglycemic DKA.

Continuing Education Disclosure Statement

Successful Completion

Learners must attend/view/read the entire activity and complete the associated evaluation to be awarded the contact hours or CERP. No partial credit will be awarded.


This activity has been reviewed by the Nurse Planner. It has been determined that the material presented here shows no bias. No conflicts of interest have been identified for any individual with the ability to influence the content of this activity. Accreditation refers to recognition of continuing education only and does not imply AACN or ANCC approval or endorsement of any commercial products discussed or displayed in conjunction with this educational activity.


The American Association of Critical-Care Nurses (AACN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC's) Commission on Accreditation, ANCC Provider Number 0012. AACN has been approved as a provider of continuing education in nursing by the California State Board of Nursing (CBRN), California Provider number CEP 1036. This activity is approved for 1.00 contact hours.

AACN programming meets the standards for most states that require mandatory continuing education contact hours for license and/or certification renewal. AACN recommends consulting with your state board of nursing or credentialing organization before submitting CE to fulfill continuing education requirements.

Refund Policy

Continuing Education Activities are nonrefundable.